Bay 59-3074

Research use only, not for human use.

A potent, selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 48.3, and 45.5 nM for human CB1 and human CB2 receptors, respectively.

A potent, selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 48.3, and 45.5 nM for human CB1 and human CB2 receptors, respectively; displays antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic; orally acitve.

——

BAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain. Animal Model:Male Wistar rats (160-250 g) Dosage:0.3 mg/kg, 1 mg/kg, and 3 mg/kg Administration:Oral administration; daily; for 2 weeks.Result:Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased.

Bay59-3074 | Bay-59-3074

GPCR/G Protein

Cannabinoid Receptor

CB1|CB2

Cancer

——

406205-74-1

453.3555

C18H13F6NO4S

>98% (HPLC)

DMSO: ≥ 34 mg/mL

O=S(CCCC(F)(F)F)(OC1=CC=CC(OC2=CC=CC(C(F)(F)F)=C2C#N)=C1)=O

1-Butanesulfonic acid, 4,4,4-trifluoro-, 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl ester

(-20℃)

With Ice Pack

≥ 2 years